



Trendlines 2017 Year-End Results:
US\$15.5 Million Increase in Net Income before Tax versus FY2016
15.6% Rise in Portfolio Value to US\$96.8 Million compared to 31.12.16

Misgav, Israel and Singapore, 21 February 2018 – The Trendlines Group Ltd. (the “Company” and together with its subsidiaries, “Trendlines” or the “Group”), a leading Israeli investment and innovation commercialization company focused on early-stage, high growth innovation-based medical and agricultural technologies, announced its financial year ended 31 December 2017 financial results (“FY2017”).

2017 Group Financial Highlights:

- Nine new portfolio companies established
- Fair Value of Portfolio: US\$96.8 million (31.12.16: US\$83.7 million)
- Total current assets: US\$20.4 million (31.12.16: US\$17.3 million)
- Net income: US\$3.9 million (FY2016: Net loss US\$6.6 million)
- Book value of US\$92.2 million as at 31.12.17 (31.12.16: \$78.2 million)

2017 Financial Results

Total income in FY2017 was US\$15.6 million, compared to US\$0.1 million in FY2016. The increase in total income primarily reflects the increase in the fair value of Trendlines’ portfolio companies. The increase was mainly due to the completion of fund raising exercises at favorable terms to the portfolio companies, and general commercial or technological progress demonstrated in some portfolio companies in FY2017.

Total expenses were US\$10.0 million in FY2017, compared to US\$10.0 million in FY2016. Net income before tax increased by US\$15.5 million from a net loss before tax of US\$9.9 million in FY2016 to a net income before tax of US\$5.6 million in FY2017. Net income after tax for FY2017 was US\$3.9 million, compared to a net loss after tax of US\$6.6 million in FY2016 representing a US\$10.5 million increase.

Current assets were US\$20.4 million as at 31 December 2017, compared to US\$17.3 million as at 31 December 2016. The fair value of portfolio companies was US\$96.8 million as at 31 December 2017, compared to portfolio value of US\$83.7 million as at 31 December 2016. The increase was mainly due to the completion of fund raising exercises at favourable terms to the portfolio companies, as previously mentioned, and investments in new portfolio companies which contributed US\$4.0 million to the fair value of portfolio companies.

Corporate/Business Developments:

- Three exit-related events were announced, two of which were completed:
(1) Completion of the sale of Trendlines’ shares in BioSight Ltd., (2) Completion of the sale of Trendlines’ holding of MitrAssist Ltd; and (3) an investment in Vensica Medical

Ltd. by Cogentix Medical, Inc. of US\$2 million with an option for them to acquire the entire share capital of Vensica.

- Trendlines raised US\$10.3 million of gross proceeds in a new shares placement.
- A strategic partnership was established with Chinese multinational Haier's Haier Hai Chuanghui Incubator and Ventures.
- Trendlines Labs signed an agreement with Singapore General Hospital and received a grant from the Singapore Israel Industrial Research and Development Foundation for clinical trials in Singapore.
- Eight new portfolio companies were established in Israel.
- Trendlines Medical Singapore Pte. Ltd. ("Trendlines Medical Singapore") launched its first portfolio company investment: InterVaal Pte. Ltd.
- The Bayer Trendlines Ag Innovation Fund set up by Bayer CropScience LLC and Trendlines, announced the establishment of a new company called IBI-Ag Ltd.
- Trendlines confirmed that the product developed by its Most Valuable Portfolio Company is on schedule for launch in 2018.
- Four portfolio companies raised a total of US\$7.5 million from strategic partners.
- Thirteen portfolio companies are in the commercialization stage.
- Cost-reduction program for 2018 in place.

Post Year-end Developments

- Trendlines Medical Singapore and K2 Global Pte. Ltd. to participate in a government-backed SGD100 million start-up program by SPRING SEEDS Capital

Commenting on corporate progress during 2017, Chairman and CEO Steve Rhodes remarked, "2017 saw the accomplishment of a number of strategic goals. We continued our strong portfolio expansion in 2017 and will continue this trend in the coming years. We started 9 new companies, bringing the total number of portfolio companies, net of write-offs and exits, to 49. During 2017, we generated a new report – '10 Companies to Watch' – which focuses on the developments of 10 of our more prominent companies. In 2017, fifteen of our portfolio companies raised over US\$20 million in follow-on investments.

"Trendlines raised US\$10.3 million of gross proceeds in a new shares placement, strengthening our ability to make direct and indirect investments in new, prospective and existing portfolio companies, as well as for general working capital."

On the Group's international expansion and Trendlines' growing partnership network, Chairman and CEO Todd Dollinger said "In 2017, Trendlines Medical Singapore was launched and has invested in its first company while we established two strategic partnerships with Singaporean entities. In addition, we continued our growth of strategic partnerships with the establishment of a partnership with Chinese multinational, Haier Hai Chuanghui Incubator and Ventures. Trendlines Labs continues to expand their multinational network in Europe, Asia, and North America.

"Partnering with multinational corporations has been an important component of the Company's success and we continue to establish partnerships with multinational corporations for us and our portfolio companies, added Todd. In addition to the investment by B. Braun Melsungen AG ("B. Braun") in Trendlines Medical Singapore, B. Braun also participated in our shares placement, invested in another three of our portfolio companies including, for the first time, Fidmi Medical Ltd., and continues working actively with our Trendlines Labs team. Furthermore, three additional companies received investments from other strategic partners.

"Building on our financial and intellectual capital, as well as our strong business reputation in the fields of medical devices and agtech, we look forward to many new business developments in 2018.

" Today Trendlines is recognized internationally as a leader in agtech investing and, on 8 May 2018, we will be holding the 5th AgriVest Conference, highlighting the Israeli agtech ecosystem; we invite investors to come and hear from agtech companies and meet the Trendlines' team."

For full financial information, please see our announcement to the SGX: Unaudited Financial Statement for the Financial Year Ended 31 December 2017.

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

Investor Contact Information

Israel

Shira Zimmerman, The Trendlines Group

shira@trendlines.com

Tel: +972.72.260.7000

Singapore

Reyna MEI, Financial PR

reyna@financialpr.com.sg

Tel: +65.6438.2990

This press release has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)